✳flâneur — a map of the web's best reading

What we wish we knew entering the aging field

librariesforthefuture.bio · 2,926 words · saved by 1 readers

The field has been around for almost a century, with research dating back to the 1930s on caloric restriction in mice. Despite all, we currently have zero FDA-approved interventions for aging or longevity. The current decade is the critical decade. Over the last ten years, the field has cleared some critical obstacles for a regulatory pathway. In 2015, a group of leading academics in the field met with the FDA about the TAME (Targeting Aging with Metformin) Trial and indicated the FDA agreed with the plan. In 2023, Loyal received a historic FDA milestone of reasonable expectation of effectiveness for lifespan extension in large dogs. And recently, BioAge announced a phase 2 clinical trial with Eli Lilly on a drug combination (azelaprag & tirzepatide) for musculoskeletal protection alongside GLP-1s. Over the next ten years, we will see more therapeutics, tools, and technologies in the field move from lab to clinic than ever before. The longevity funnel framework (LFF) is how we think ab

What we wish we knew entering the aging field The longevity funnel framework (LFF) age1 and Maggie Li Mar 14, 2024 31 3 Share The field has been around for almost a century, with research dating back to the 1930s on caloric restriction in mice. Despite all, we currently have zero FDA-approved interventions for aging or longevity. The current decade is the critical decade. Over the last ten years, the field has cleared some critical obstacles for a regulatory pathway. In 2015, a group of leading academics in the field met with the FDA about the TAME (Targeting Aging with Metformin) Trial and in

Explore this link on the map →

saved by

related reading